hbv-mpl 208129
Vaccineexperimental
Clinical trial activity
15 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
14
Phase 3
8
Phase 4
0
Earliest trial started Feb 1, 1992 (NCT00699231)
Timeline
Indications
Studied for
Mechanism of action
- Hepatitis B virusImmunity, active
Hepatitis B virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- hbv-mpl 208129
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00697866 | Phase 3 | Aug 1, 2000 | GlaxoSmithKline |
| NCT00697554 | Phase 3 | Jan 1, 2000 | GlaxoSmithKline |
| NCT00698061 | Phase 3 | Nov 1, 1999 | GlaxoSmithKline |
| NCT00696917 | Phase 3 | Apr 1, 1999 | GlaxoSmithKline |
| NCT00697749 | Phase 3 | Apr 1, 1999 | GlaxoSmithKline |
| NCT00697853 | Phase 2 | Nov 1, 1998 | GlaxoSmithKline |
| NCT00697775 | Phase 2 | Mar 1, 1998 | GlaxoSmithKline |
| NCT00696891 | Phase 3 | Jun 1, 1997 | GlaxoSmithKline |
| NCT00698906 | Phase 2 | Jun 1, 1997 | GlaxoSmithKline |
| NCT00697216 | Phase 3 | Mar 1, 1997 | GlaxoSmithKline |
| NCT00698555 | Phase 2 | Mar 1, 1997 | GlaxoSmithKline |
| NCT00697840 | Phase 3 | Jun 1, 1995 | GlaxoSmithKline |
| NCT00697125 | Phase 2 | Jun 1, 1993 | GlaxoSmithKline |
| NCT00697229 | Phase 2 | Sep 1, 1992 | GlaxoSmithKline |
| NCT00699231 | Phase 1 | Feb 1, 1992 | GlaxoSmithKline |
Showing 15 of 15 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 15 | 15 | 3 | 1992 |
1 organizations
Page 1 / 1